Product
Acthar
Aliases
Acthar Injectable Product, H.P. Acthar Gel, repository corticotropin injection
Name
Acthar
INN Name
Repository Corticotropin
FDA Approved
Yes
6 clinical trials
2 organizations
4 indications
2 documents
Indication
Rheumatoid ArthritisIndication
SarcoidosisIndication
PulmonaryIndication
Focal Segmental GlomerulosclerosisClinical trial
The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis: A Pilot StudyStatus: Active (not recruiting), Estimated PCD: 2020-02-26
Clinical trial
A Multicenter, Randomized, Double Blind, Placebo Controlled Exploratory Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary SarcoidosisStatus: Completed, Estimated PCD: 2021-11-15
Clinical trial
Use of Acthar in Rheumatoid Arthritis Related FlaresStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
The Use of Acthar (ACTH) in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Have Developed Chronic Kidney Disease Stage V (CKD) or End Stage Renal Disease (ESRD) and Are Undergoing a Renal TransplantStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Open Label Study to Evaluate Efficacy and Safety of Short-Term, Adjunctive Adrenocorticotropic Hormone (ACTH) Gel in Rheumatoid ArthritisStatus: Completed, Estimated PCD: 2022-06-30
Clinical trial
Use of CXCL9 as a Biomarker of Acthar EfficacyStatus: Recruiting, Estimated PCD: 2025-12-01
Document
DailyMed Label: ActharOrganization
Mallinckrodt ARD LLCOrganization
ANI Pharmaceuticals, Inc.